Philips introduces OmniWire, the world’s first solid core pressure guide wire for coronary artery interventional procedures...
17 August 2020 - 11:00PM
August 17, 2020
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG,
AEX: PHIA), a global leader in health technology, today announced
the introduction of OmniWire, the world’s first solid core pressure
wire for coronary artery interventional procedures. With its
breakthrough solid core construction, physicians can more easily
maneuver the wire in the patient’s circulatory system to measure
blood pressure along the vessel and guide the delivery of catheters
and stents. The new wire supports iFR (instant wave-Free Ratio)
measurements, the only resting index supported by randomized
controlled outcome trials [1-3], as well as FFR (fractional flow
reserve) measurements. It also integrates with the Philips
IntraSight interventional applications platform, which can
co-register iFR data onto the angiogram (interventional X-ray
image) to precisely identify the parts of vessels requiring
treatment.
Traditional pressure wires use a hollow metal tube (hypotube) to
house the wiring that transmits the pressure information. Due to
their thin walls, these wires can be challenging to maneuver and
can sometimes kink, potentially becoming damaged during the
procedure. OmniWire is the world’s first solid core pressure
guidewire, using advanced conductive ribbons embedded in its outer
polymer layer to communicate pressure information. The front
(distal) part of the wire is made from Nitinol, a super-elastic,
durable material that is commonly used in non-diagnostic,
interventional ‘workhorse’ guide wires. The back (proximal) part of
the wire is constructed from a high-strength cobalt alloy that
provides the high durability required for complex and multi-vessel
cases.
“I have been very impressed with the handling of OmniWire, the
new solid core design performed beautifully, and I was able to
navigate the difficult case easily,” said Dr. Jasvindar Singh,
director of the catheterization lab at Barnes Jewish Hospital and
associate professor at Washington University in St. Louis, U.S.,
who performed the first human case with OmniWire in the country.
“We used iFR co-registration and found that the patient needed a
stent. I was then able to perform the whole procedure working over
OmniWire. This is truly an innovation in percutaneous coronary
interventions.”
The new wire supports both iFR and FFR indices. iFR continues to
be adopted into clinical practice and has been validated in
clinical outcomes studies with data from over 4,500 patients [1,2]
as well as being recognized by the European Society of Cardiology
(ESC), the Society for Cardiovascular Angiography and Interventions
(SCAI) and the American College of Cardiology (ACC) [4-6].
OmniWire integrates with IntraSight, Philips’ secure
interventional applications platform that integrates a
comprehensive suite of clinically proven modalities including iFR,
FFR, IVUS (intravascular ultrasound) and co-registration [7] to
simplify complex interventions and speed routine procedures. With
iFR pullback and co-registration, physicians can identify the
precise locations causing ischemia, plan stent length and placement
with a virtual stent, and predict physiologic
improvement.
“With integration and co-registration on our IntraSight
platform, measurement with iFR, and now enhanced wire performance
thanks to OmniWire, we’re providing clinicians with an advanced
solution at every step of the procedure,” said Chris Landon, Senior
Vice President and General Manager Image Guided Therapy Devices,
Philips. “Physicians can confidently use a functional guidance
strategy across all their patients, including in complex and
multi-vessel cases. Today’s announcement demonstrates how our
unique portfolio of systems, smart devices, software and services
combines to deliver advanced procedure-oriented solutions.”
OmniWire is now available in the U.S. and Japan and has received
clearance from the U.S. Food and Drug Administration (FDA) and
approval from the Japan Pharmaceuticals and Medical Devices Agency.
For more information, visit philips.com/OmniWire.
[1] Davies JE, et al., Use of the Instantaneous Wave-free Ratio
or Fractional Flow Reserve in PCI. N Engl J Med. 2017 May
11;376(19):1824-1834. [2] Gotberg M, et al., iFR-SWEDEHEART
Investigators. Instantaneous Wave-free Ratio versus Fractional Flow
Reserve to Guide PCI. N Engl J Med. 2017 May 11;376(19):1813-1823.
[3] Jeremias A, et al. Blinded physiological assessment of residual
ischemia after successful angiographic percutaneous coronary
intervention. The DEFINE PCI study. J Am Coll Cardiol Intv
2019;12:1991–2001.[4] 2018 ESC/EACTS Guidelines on myocardial
revascularization: The task force on myocardial revascularization
of the European society of cardiology (ESC) and European
association for cardio-thoracic surgery (EACTS). Eur Heart J.
2018;00:1-96. [5] Lofti A, et al. Focused update of expert
consensus statement: Use of invasive assessments of coronary
physiology and structure: A position statement of the society of
cardiac angiography and interventions. Catheter Cardiovasc Interv.
2018;1–12. [6] ACC-SCAI recommendation letter for Volcano iFR CPT
coding (93571, 93572).[7] Co-registration tools available within
IntraSight 7 configuration via SyncVision.
For further information, please contact:
Hans DriessenPhilips Global Press OfficeTel.: +31 6
10610417Email: hans.driessen@philips.com Twitter:
@hansdriessen_ph
Fabienne van der FeerPhilips Image Guided TherapyTel: +31 622
698 001Email: fabienne.van.der.feer@philips.com Twitter:
FC_Feer
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people’s health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2019
sales of EUR 19.5 billion and employs approximately 81,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
- Philips OmniWire 3D view
- Philips OmniWire 2D technical illustration
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Oct 2023 to Oct 2024